Maynard Um
-
-
-
-
-
-
-
IO Biotech explores strategic alternatives including potential sale
-
-
-
-
-
-
-
IO BIOTECH delays drug application after FDA feedback, cuts workforce by 50%
-
-
-
-
-
-
-
IO Biotech (IOBT) Reports 2024 Business Highlights
-
-
-
-
-
-
-
Morgan Stanley on IO Biotech (IOBT): 'We are encouraged by continued meaningful benefits in a second indication (melanoma lead indication)'
-
-
-
-
-
401,666 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

